| Display title | Biology:Acalabrutinib |
| Default sort key | Acalabrutinib |
| Page length (in bytes) | 15,171 |
| Namespace ID | 3026 |
| Namespace | Biology |
| Page ID | 845540 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Unex |
| Date of page creation | 12:24, 13 February 2024 |
| Latest editor | imported>Unex |
| Date of latest edit | 12:24, 13 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Acalabrutinib, sold under the brand name Calquence, is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic Lymphoma (CLL/SLL). It may be used both in relapsed as well as in treatment-naive settings... |
